| Literature DB >> 22866906 |
Nada Oršolić1, Damir Sirovina, Marijana Zovko Končić, Gordana Lacković, Gordana Gregorović.
Abstract
BACKGROUND: In the present study, we examined the antioxidant effect of water soluble derivative of propolis (WSDP) and ethanolic (EEP) extract of propolis on renal and liver function in alloxan-induced diabetic mice. In addition, we examined whether different extract of propolis could prevent diabetic nephropathy and liver toxicity by inhibiting lipid peroxidation in vivo.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22866906 PMCID: PMC3551731 DOI: 10.1186/1472-6882-12-117
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Figure 1Effect of WSDP or EEP on body weight of alloxan-induced diabetic mice. Control group of nondiabetic mice received 0.5 mL physiological solution intraperitonealy (ip) for 7 consecutive days starting starting 2 days after aloxan injection.Diabetic mice; injected iv with alloxan in a single dose of 75 mg kg-1 body weight and served as untreated diabetic group.Untreated diabetic mice received 0.5 mL physiological solution intraperitonealy (ip) or 0.5% ethanolic solution for 7 consecutive days starting starting 2 days after aloxan injection. Diabetic mice treated with water-soluble derivative of propolis (WSDP) or ethanoloc extract of propolis (EEP) ip in a daily dose of 50 mg kg-1 for 7 days starting 2 days after alloxan injection.
Survival of untreated diabetic mice and diabetic mice treated with WSDP or EEP
| Diabetic micea | 15-45 | 38.5 ± 13.12 | - | - | 3 |
| Diabetic mice + (0.5% EtOH) | 22-45 | 42 ± 9.68 | - | - | 4 |
| Diabetic mice + WSDPb | 45 | 45* | 30.43 | 130.43 | 8 |
| Diabetic mice + EEPb | 45 | 45* | 20,67 | 120,67 | 8 |
aDiabetic mice; injected iv with alloxan in a single dose of 75 mg kg-1 body weight and served as untreated diabetic group. Untreated diabetic mice received 0.5 mL physiological solution or 0.5% ethanolic solution intraperitonealy (ip) for 7 consecutive days starting starting 2 days after aloxan injection.
bDiabetic mice treated with WSDP or EEP ip in a daily dose of 50 mg kg-1 for 7 days starting 2 days after alloxan injection.
cILS% (increased life span%) = (T-C)/Cx100. T, mean survival time of treated diabetic group; C, mean survival time of untreated diabetic group.
dT/C treated diabetic animals versus untreated diabetic animals.
eLTS- Long-term survivors; mice surviving more than 45 days after alloxan treatment.
Results are expressed as the means of each group (n = 8) of and are representative of two independent experiments.
*Statistically significant difference between WSDP or EEP treated diabetic mice and untreated diabetic animals (*P <0.05; Log-Rank test).
Haematological parameters of nondiabetic mice, untreated diabetic mice and diabetic mice treated with WSDP or EEP
| WBC (×109 L-1) | 4.85 ± 1.00 | 4.96 ± 0.81 | 4.41 ± 1.31 | 4.59 ± 3.18 | 3.3 ± 1.42 |
| Mononuclear/% | 57.06 ± 12.08 | 63.16 ± 6.24 | 51.73 ± 12.62 | 56 ± 19.90 | 53.38 ± 9.63 |
| Polymorphonuclear/% | 42.94 ± 12.00 | 36.84 ± 6.24 | 48.27 ± 12.62 | 44 ± 19.90 | 46.62 ± 9.63 |
| RBC (x 1012 L-1) | 9.13 ± 0.32 | 9.18 ± 0.33 | 9.435 ± 0.28 | 9.87 ± 0.46 | 9.755 ± 0.14* |
| HGB (g L-1) | 135.55 ± 5.35 | 132.05 ±5.25 | 136.2 ± 3.67 | 139.85 ± 5.56 | 139.45 ± 1.75* |
| HCT (L L-1) | 0.444 ± 0.02 | 0.44 ± 0.01 | 0.452 ± 0.01 | 0.47 ± 0.02* | 0.4715 ± 0.00** |
| MCV (fL) | 97.2 ± 1.91 | 96.2 ± 2.33 | 95.8 ± 1.50 | 95.4 ± 1.59 | 96.75 ± 1.84 |
| MCH (pg) | 29.7 ± 0.26 | 28.8 ± 0.69 | 28.9 ± 0.41 | 28.3 ± 0.50 | 28.6 ± 0.43 |
| MCHC (g L-1) | 616.7 ± 6.43 | 598.5 ± 5.26 | 603 ± 7.74 | 593.5 ± 1.91 | 591.5 ± 4.43 |
| RDW (%CV) | 24 ± 3.00 | 23.1 ± 1.16 | 23.6 ± 1.78 | 22.35 ± 1.30 | 22.35 ± 1.11 |
| PLT (x 109 L-1) | 1434.5 ± 373.75 | 1333.5 ± 330.52 | 1521.5 ± 251.01 | 805 ± 344.36* | 986 ± 151.85 |
| MPV (fL) | 9.76 ± 0.67 | 10.19 ± 0.24 | 9.92 ± 0.63 | 10.76 ± 1.05 | 9.97 ± 0.57 |
aControl group of nondiabetic mice received 0.5 mL physiological solution intraperitonealy (ip) for 7 consecutive days starting starting 2 days after alloxan injection.
bDiabetic mice; injected iv with alloxan in a single dose of 75 mg kg-1 body weight and served as untreated diabetic group. Untreated diabetic mice received 0.5 mL physiological solution or 0.5% ethanolic solution intraperitonealy (ip) for 7 consecutive days starting starting 2 days after aloxan injection.
cDiabetic mice treated with WSDP or EEP ip in a daily dose of 50 mg kg-1 for 7 days starting 2 days after alloxan injection.
*Statistically significant difference between WSDP or EEP treated diabetic mice and untreated diabetic animals (*P <0.05; ** P <0.01; Student t-test).
Statistically significant difference between nondiabetic animals and WSDP or EEP treated diabetic mice (P <0.05; P <0.01; Student t-test).
Biochemical parameters of nondiabetic mice, untreated diabetic mice and diabetic mice treated with WSDP or EEP
| ALP (U L-1) | 53.75 ± 7.50 | 83.33 ± 16.07# | 95 ± 10.80 | 71.25 ± 20.15 | 65 ± 10.80 |
| AST (U L-1) | 146.25 ± 13.50 | 186.25 ± 31.72 | 183.75 ± 41.70 | 167.5 ± 29.58 | 161.25 ± 29.54 |
| ALT (U L-1) | 57.5 ± 9.36 | 81.25 ± 9.46 | 90 ± 15.35 | 66.25 ± 11.09* | 60 ± 10.80* |
| LD (g L-1) | 1881 ± 298.48 | 2246.25 ± 157.92# | 2487.5 ± 253.42# | 995 ± 358.86*** | 586.25 ± 90.68** |
| TP (g L-1) | 48.5 ± 4.38 | 44.5 ± 1.96 | 48.75 ± 4.92 | 40.75 ± 4.78 | 40.875 ± 1.93 |
| GLU (mmol L-1) | 9.89 ± 0.64 | 30.52 ± 5.34 | 25.575 ± 4.55 | 32.57 ± 7.47 | 47.75 ± 6.35 |
| UREA (mmol L-1) | 7.5 ± 1.22 | 9.125 ± 0.42 | 9.88 ± 1.89 | 13.625 ± 3.45 | 7.88 ± 2.43 |
| Cholesterol (mmol L-1) | 3.52 ± 0.26 | 3.20 ± 1.00 | 3.20 ± 0.80 | 4.14 ± 2.36 | 3.55 ± 0.72 |
| Triglycerides (mmol L-1) | 2.72 ± 0.16 | 3.00 ± 0.90 | 3.37 ± 1.11 | 2.20 ± 0.97 | 2.56 ± 0.92 |
aControl group of nondiabetic mice received 0.5 mL physiological solution intraperitonealy (ip) for 7 consecutive days starting starting 2 days after aloxan injection.
bDiabetic mice; injected iv with alloxan in a single dose of 75 mg kg-1 body weight and served as untreated diabetic group.Untreated diabetic mice received 0.5 mL physiological solution or 0.5% ethanolic solution intraperitonealy (ip) for 7 consecutive days starting starting 2 days after aloxan injection.
cDiabetic mice treated with WSDP or EEP ip in a daily dose of 50 mg kg-1 for 7 days starting 2 days after alloxan injection.
*Statistically significant difference between WSDP or EEP treated diabetic mice and untreated diabetic animals (*P <0.05; P** < 0.01; Student t-test).
Statistically significant difference between untreated diabetic mice and nondiabetic animals (P <0.01; Student t-test).
Statistically significant difference between nondiabetic animals and WSDP or EEP treated diabetic mice (P <0.05; P <0.01; P <0.001; Student t-test).
Figure 2Liver of diabetic mice stained with HE. (A-B) Diabetic mice treated with physiological solution. (A) Hepatocytes around Kiernan’s spaces (Ks) are more vacuolized then cells around central vein (vc). (B) Focal hemorrhagic necrosis. (C) Diabetic mice treated with WSDP show less vacuolized hepatocytes. Dilatated sinusoids and swollen hepatocytes without vacuoles can be seen around central vein (vc). Cells around Kiernan’s space (Ks) are not swollen, some are weakly vacuolized. (D-E) Diabetic mice treated with ethanolic solution (0.5% EtOH). (D) Hepatocytes around central vein (vc) are more intensively vacuolized then cells around Kiernan’s space (Ks). (E) Increased number and level of vacuolized hepatocytes in whole lobule. (F) Diabetic mice treated with EEP. Hepatocytes are less vacuolized compared to diabetic mice. Bar = 20 μm.
Figure 3Number of apoptotic cells in the liver of diabetic mice treated with physiological and ethanolic solution (0.5% EtOH) and diabetic mice treated with WSDP and EEP. Data are mean ± SD and represent percentages of apoptotic cells in total of 200 cells.
Figure 4Kidney of diabetic mice stained with HE. (A-E) Diabetic mice treated with physiological solution. (A) The renal corpuscle with narrow Bowman’s space (black arrowhead) and columnar cells in the parietal layer of Bowman’s capsule (white arrowhead). Tubular changes involve: (A-D) presence of necrotic cells (nc), (B) presence of basophilic cells (bc), cytoplasmic vacuolization (arrows), (C) presence of vacuole-like spaces in the tubular lumen (asterisk), (D) epithelial flattening with or without intraluminal eosinophilic mass (ef), and (E) dilated tubules (dt). (E) The interstitium shows large lymphocyte infiltration (L). (F) Kidney cortex of diabetic mice treated with WSDP. More dilated tubules (dt) and larger interstitial lymphocyte infiltrations (L) compared to diabetic mice. Bar = 20 μm.
Figure 5Levels of lipid peroxidation in liver and kidney of nondiabetic mice, untreated diabetic mice and diabetic mice treated with WSDP and EEP. Values are means ± SD (n = 4). (Diferences with untreated diabetic mice *P <0.05; **P <0.01; Diferences with nondiabetic mice †P <0.05; ‡P <0.01; Student’s t-test)
Figure 6Inhibition of bleaching of β-carotene-linoleic acid emulsion by the WSDP, EEP and BHA over 120 min. Values are means ± SD (n = 3).
Antioxidant activity in β-carotene-linoleate test (ANT), radical scavenging activity (EC), slope of reducing power trendline (SRP) and metal chelating activity (ChEC) of WSDP and EEP
| EEP | 87.3 ± 0.39#### | 27.82 ± 0.44#### | 0.56 ± 0.00#### | |
| WSDP | 96.81 ± 0.33#### | 55.97 ± 1.50#### | 0.53 ± 0.02#### | 47.81 ± 0.34#### |
| STD | a91.67 ± 0.49 | a6.02 ± 0.10 | b7.53 ± 0.24 | c7.18 ± 0.10 |
Values are means ± SD (n = 3).
n.d. − not detected.
STD − standard: a = BHA, b = ascorbic acid, c = EDTA.
# Statistically significant difference between sample and standard (####P <0.0001; Student t-test).
Figure 7Reducing powers of EEP, WSDP and ascorbic acid. Values are means ± SD (n = 3).